<DOC>
	<DOCNO>NCT01679639</DOCNO>
	<brief_summary>This open-label , fixed-sequence , three-period , single group study evaluate effect rifampicin pharmacokinetics aleglitazar healthy volunteer . Volunteers receive single dos aleglitazar three period single dos rifampicin period 1 2 , multiple dos period 3 . The anticipated time study treatment 14 week .</brief_summary>
	<brief_title>A Study Investigate Effects Rifampicin Pharmacokinetics Aleglitazar Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Rifampin</mesh_term>
	<criteria>Healthy volunteer , age 18 55 year inclusive time screen Body mass index ( BMI ) 18.0 35.0 kg/m2 inclusive Females must surgically sterile use two acceptable method contraception Nonsmoker currently smoke less five cigarettes/day willing abstain smoking study Any clinically relevant abnormal laboratory test result screen Day 1 period , judge Investigator A history clinically significant disorder ( e.g. , gastrointestinal , cardiovascular , hepatic ) Infection human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C An average alcohol intake 14 unit per week Volunteers diagnose , suspect porphyria , subject first degree relative diagnose , suspect porphyria Diagnosis Gilberts Syndrome A positive screen drug abuse screen admission clinical unit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>